Tissue-Engineered Mandibular Bone Reconstruction for Continuity Defects: A Systematic Approach to the Literature by Chanchareonsook, Nattharee et al.
Tissue-Engineered Mandibular Bone
Reconstruction for Continuity Defects:
A Systematic Approach to the Literature
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Leenaporn Jongpaiboonkit, PhD,4 and John A. Jansen, DDS, PhD3
Background: Despite significant surgical advances over the last decades, segmental mandibular bone repair
remains a challenge. In light of this, tissue engineering might offer a next step in the evolution of mandibular
reconstruction.
Purpose: The purpose of the present report was to (1) systematically review preclinical in vivo as well as clinical
literature regarding bone tissue engineering for mandibular continuity defects, and (2) to analyze their effectiveness.
Materials and Methods: An electronic search in the databases of the National Library of Medicine and ISI Web of
Knowledgewas carried out. Only publications in Englishwere considered, and the searchwas broadened to animals
and humans. Furthermore, the reference lists of related review articles and publications selected for inclusion in this
reviewwere systematically screened. Results of histology data and amount of bone bridgingwere chosen as primary
outcome variables. However, for human reports, clinical radiographic evidence was accepted for defined primary
outcome variable. The biomechanical properties, scaffold degradation, and clinical wound healing were selected as
co-outcome variables.
Results: The electronic search in the databases of the National Library of Medicine and ISI Web of Knowledge
resulted in the identification of 6727 and 5017 titles, respectively. Thereafter, title assessment and hand search
resulted in 128 abstracts, 101 full-text articles, and 29 scientific papers reporting on animal experiments as well as 11
papers presenting human data on the subject of tissue-engineered reconstruction of mandibular continuity defects
that could be included in the present review.
Conclusions: It was concluded that (1) published preclinical in vivo as well as clinical data are limited, and (2) tissue-
engineered approaches demonstrate some clinical potential as an alternative to autogenous bone grafting.
Introduction
Mandibular continuity defects result from a varietyof causes, including maxillofacial trauma, osteomyeli-
tis, osteonecrosis, and resection of benign or malignant tu-
mors.1,2 Unrepaired defects are associated with defacement,
reduced masticatory capability, and loss of speech, which
severely affect the patient’s quality of life. Ideally, mandib-
ular continuity defect reconstruction should not only restore
the anatomical height and contour of the missing part, but
should, in addition, allow re-establishment of oral function.1
Until now, autogenous bone transplantation—especially free
vascularized tissue transfer—is considered a ‘‘gold standard
of care’’ for mandibular reconstruction in patients undergo-
ing major ablative surgery.2–4 In principle, autogenous bone
grafts provide all critical factors for bone regeneration, such
as a scaffold for osteo-conduction, growth factors for osteo-
induction, and cells for osteogenesis.5 However, the major
problem of this approach is the requirement of autoge-
nous donor tissue, which results, for example, in donor-site
morbidity.6 Moreover, despite the availability of various
reconstructive methods by means of autogenous tissue,
perfect mandibular reconstruction, including restoration of
continuity, sensation, dentition, soft tissue, function, and
aesthetics, is still not achievable.1,2 As a consequence, man-
dibular bone reconstruction still remains a challenge.2
However, development of reliable tissue engineering
techniques might offer a next step in the evolution of man-
dibular reconstruction.2,7 By definition, tissue engineering
was defined as an interdisciplinary field that applies the
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principles of engineering and the life sciences toward the
development of biological substitutes which restore, main-
tain, or improve tissue function.8 Bone tissue engineering is a
relatively new method that uses scaffolds, bioactive sub-
stances, and/or cells/tissues with osteogenic potential.1
Ideally, the scaffolds should be (1) three dimensional and
highly porous with an interconnected pore network for cell
growth and flow transport of nutrients and metabolic waste
as well as (2) biocompatible and bioresorbable with a con-
trollable degradation and resorption rate to match cell or
tissue growth. Furthermore, these scaffolds should possess
(3) suitable surface chemistry for cell attachment, prolifera-
tion, and differentiation, and (4) mechanical properties to
match those of the tissues at the site of implantation.9
At present, a multitude of scaffolds made of various mate-
rial10–19 in combination with bioactive substances or osteo-
genic bone marrow stromal cells (BMSCs)10,20–26 to initiate or
enhance bone formation15–17,19,27–33 are under study.
In 2006, Ikada defined a concept on methodology in tissue
engineering as (1) placing the construct scaffold in a biore-
actor to reconstruct an engineered tissue in vitro called
in vitro (or ex vivo) tissue engineering and (2) implantation of
the construct scaffold in the body until a new tissue is re-
generated in vivo called in vivo (or in situ) tissue engineer-
ing.34 However, the construct completely lacks a pre-existing
vasculature. Cell survival and tissue formation will depend
on local vasculature and the speed at which a fully functional
vascular supply will be developed.35 This makes that the
reconstruction of large-volume defects, such as mandibular
continuity defects, remains challenging. Therefore, vascu-
larization concepts gain interest and the combination of tis-
sue engineering approaches with flap prefabrication
techniques. This may eventually allow application of bone-
tissue substitutes grown in vivo with the advantage of min-
imal donor site morbidity as compared with conventional
vascularized bone grafts.12 This review included the con-
cepts of tissue engineering using axial vascularization in
engineered bone tissues.
Nonetheless, to the best of the authors’ knowledge, animal
experiments as well as clinical case reports or studies on the
subject of bone tissue engineering for mandibular continuity
defects are currently neither systematically reviewed nor
synopsized.
Therefore, the purpose of the present report was (1) to
review systematically preclinical in vivo and clinical literature
regarding bone tissue engineering for mandibular continuity
defects, and (2) to analyze their effectiveness.
Materials and Methods
Study design
The scientific, preclinical in vivo and clinical literature re-
garding tissue engineered approaches for mandibular bone
regeneration in continuity defects (i.e., segmental mandibu-
lar defects or total mandibular condyle replacements) was
systematically reviewed.
Outcome variables
In principle, for animal experiments as well as human
reports, macroscopical or histological or histomorphometric
data on the amount of total bone defect bridging were cho-
sen as a primary outcome variable. However, for human
reports, clinical and/or radiographic evidence of the resto-
ration of mandibular continuity was accepted as a surrogate
outcome variable for the presently defined primary outcome
variable. Concomitantly, histological or histomorphometric
data of bone ingrowth, results of biomechanical testing,
histological or histomorphometric records of scaffold deg-
radation as well as clinical wound healing were selected as
co-outcome variables.
Inclusion/exclusion criteria
In general, only animal in vivo experiments and human
reports presenting macroscopical or histological or histo-
morphometric data on the amount of total bone defect
bridging, histological or histomorphometric data of bone
ingrowth, results of biomechanical testing, histological or
histomorphometric data of scaffold degradation or infor-
mation related to clinical wound healing, as well as human
reports presenting clinical and/or radiographic evidence of
restoration of mandibular continuity were included.
The following detailed inclusion criteria were used:
1. Research paper presenting in vivo animal data;
2. Research paper presenting human data;
3. Defect characteristics should be clearly stated;
4. Implantation site should be clearly mentioned;
5. Reconstructive technique (i.e.: tissue engineering)
should be clearly stated;
6. Healing period should be clearly stated;
7. The animal model used should be described conspicu-
ously (species, age);
8. Amount of total bone defect bridging, and/or percent-
age of bone ingrowths, and/or results of biomechanical
testing, and/or percentage scaffold degradation, and/
or information related to clinical wound healing had to
be presented;
9. For human reports, clinical and/or radiographic evi-
dence of restoration of mandibular continuity had to be
presented
Studies that did not meet all the inclusion criteria men-
tioned earlier, for example, ex-vivo studies or studies not
addressing tissue-engineered approaches for mandibular
bone regeneration in continuity defects, were excluded.
Search strategy
An electronic search in the database of the National Li-
brary of Medicine (www.ncbi.nlm.nih.gov) up to September
30, 2012 was carried out. Only publications in English were
considered, and the search was broadened to animals and
humans. The following search strategy was applied: ((‘‘tissue
engineering’’[MeSH Terms] OR (‘‘tissue’’[All Fields] AND
‘‘engineering’’[All Fields]) OR ‘‘tissue engineering’’[All
Fields]) OR (‘‘tissue scaffolds’’[MeSH Terms] OR (‘‘tis-
sue’’[All Fields] AND ’’scaffolds’’[All Fields]) OR ‘‘tissue
scaffolds’’[All Fields] OR (‘‘tissue’’[All Fields] AND ‘‘scaf-
fold’’[All Fields]) OR ‘‘tissue scaffold’’[All Fields]) OR (‘‘re-
constructive surgical procedures’’[MeSH Terms] OR
(‘‘reconstructive’’[All Fields] AND ‘‘surgical’’[All Fields]
AND ‘‘procedures’’[All Fields]) OR ‘‘reconstructive surgical
procedures’’[All Fields] OR ‘‘reconstruction’’[All Fields])
OR (‘‘bone morphogenetic proteins’’[MeSH Terms] OR
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(‘‘bone’’[All Fields] AND ‘‘morphogenetic’’[All Fields] AND
‘‘proteins’’[All Fields]) OR ‘‘bone morphogenetic pro-
teins’’[All Fields] OR (‘‘bone’’[All Fields] AND ‘‘morphoge-
netic’’[All Fields] AND ‘‘protein’’[All Fields]) OR ‘‘bone
morphogenetic protein’’[All Fields]) OR (‘‘bone marrow
cells’’[MeSH Terms] OR (‘‘bone’’[All Fields] AND ‘‘mar-
row’’[All Fields] AND ‘‘cells’’[All Fields]) OR ‘‘bone marrow
cells’’[All Fields]) OR (‘‘intercellular signaling peptides and
proteins’’[MeSH Terms] OR (‘‘intercellular’’[All Fields] AND
‘‘signaling’’[All Fields] AND ‘‘peptides’’[All Fields] AND
‘‘proteins’’[All Fields]) OR ‘‘intercellular signaling peptides
and proteins’’[All Fields] OR (‘‘growth’’[All Fields] AND
‘‘factors’’[All Fields]) OR ‘‘growth factors’’[All Fields])) AND
((‘‘mandible’’[MeSH Terms] OR ‘‘mandible’’[All Fields]) OR
((‘‘mandible’’[MeSH Terms] OR ‘‘mandible’’[All Fields] OR
‘‘mandibular’’[All Fields]) AND (‘‘Continuity’’[Journal] OR
‘‘continuity’’[All Fields]) AND defect [All Fields])).
In addition, the ISI Web of Knowledge database was
searched operating the same MeSH terms. Again, only
publications in English reporting on animal experiments and
human studies were considered.
Furthermore, the reference lists of related review articles
and publications selected for inclusion in this review were
systematically screened.
Study selection
Two independent reviewers (N.C. and L.J.) initially
screened the publication titles and abstracts as identified by
the electronic as well as manual search for possible inclusion.
Full texts of all papers that were considered eligible for in-
clusion by one or both of the reviewers were obtained for
further assessment against the stated inclusion criteria (Fig.
1). Both reviewers used an identical data extraction form to
acquire the data independently. Any disagreement between
the reviewers regarding inclusion of a certain publication or
data extraction was resolved by discussion.
Results
Study selection
The electronic search in the databases of the National Li-
brary of Medicine and ISI Web of Knowledge resulted in the
identification of 6727 and 5017 titles, respectively.
As already mentioned, these titles were initially screened
by two independent reviewers (N.C. and L.J.) for possible
inclusion. In order not to exclude scientific reports unin-
tended, title screening as well as abstract assessment was
accomplished to identify articles reporting, in general, on
mandibular defect reconstruction (i.e., noncontinuity as well
as continuity defects). Title assessment and hand search re-
sulted in the final selection of 128 abstracts, 101 full-text ar-
ticles, and 40 scientific papers reporting on tissue-engineered
reconstruction of mandibular continuity defects that could be
included in the present review (Fig. 1, Tables 1–4). Regarding
data extraction and interpretation, any disagreement be-
tween the reviewers was resolved by discussion.
General characteristics of the included studies
In total, 29 papers reported on animal experiments. Twenty-
seven of these articles presented data on segmental mandib-
ular body reconstruction,4,10,11,15–19,25,26,29–33,97–103,105–107,109,110
one article reported on mandibular angle reconstruction,104
and another one presented data on mandibular condyle
reconstruction.108 Research was done in rabbits,30,108
sheep,11,16,17,19,100,107 goats,104,105 as well as in minipigs,33
dogs4,10,25,26,31,32,97,98,106,110, and monkeys.15,18,29,99,101–103,109 In
several studies, teeth were extracted in advance, and oral
mucosa was allowed to heal completely before resective sur-
gery and reconstructive therapy.4,26,105,106 Beside the diversity
in animal models, study design as well as healing periods after
reconstructive surgery (range: 4–48 weeks) were not uniform.
The follow-up periods were related to differences in animal
species; for example, dog (12–48 weeks), monkey (16–30
weeks), sheep (12–20 weeks), rabbit (12–16 weeks), goat (6–16
weeks), and minipigs (16 weeks).
Furthermore, 11 out of the 40 articles presented human
data on mandibular reconstruction.111–121
The general characteristics of the included animal and
clinical studies are summarized in Tables 3 and 4.
Animal studies
Autogenous bone precursor cells or autogenous osteo-
genic tissues. As described, bone tissue engineering is an
approach that combines scaffolds with osteogenic cells/
tissues and/or bioactive substances. In preclinical animal
models, in principle, two different strategies for bone recon-
struction in continuity defects have been intensively investi-
gated, that is, the implantation of autogenous bone precursor
cells or autogenous osteogenic tissues—which contain osteo-
progenitor cells and/or mesenchymal stem cells—and the
application of bone morphogenetic proteins. Both were com-
bined with a range of different carrier biomaterials.
In total, 12 scientific papers4,10,11,18,25,26,100,104–108 reporting
on autogenous bone precursor cells or autogenous osteo-
genic tissues were finally appropriate for inclusion in the
current systematic review. Due to their experimental diver-
sity, these studies are briefly summarized (Details can be
found in Addendum No. 1 in Supplementary Data; Supple-
mentary Data are available online at www.liebertpub.com/
teb).
In summary, autogenous bone precursor cells or autoge-
nous osteogenic tissues were primarily combined with cal-
cium phosphate ceramic scaffolds, such as beta-tri calcium
phosphate (b-TCP)4,11,25,26,106 and biphasic calcium phos-
phate ceramic,26 or pyrolized bovine bone100 or calcium
carbonate, such as natural corals.10,105 Considering the pri-
mary outcome variable bone bridging4,11,18,26,104–107,117 as
well as the co-outcome variables bone ingrowth100 and
biomechanical testing,4,10,25 autogenous bone precursor cells
or autogenous tissues seeded onto calcium phosphate ce-
ramic scaffolds showed in preclinical animal studies the
potential of an alternative to autograft bone for mandibular
bone reconstruction in continuity defects. Moreover, autog-
enous bone precursor cells or autogenous osteogenic tissues
seeded onto or mixed with collagen sponges18,108 demon-
strated in preclinical animal studies promising results in
terms of the primary outcome variable bone bridging18 or
the co-outcome variable bone ingrowths.108 In contrast, au-
togenous bone precursor cells containing tissues filled in
preshaped poly–D, L–lactide trays did not show such a
potential as an alternative to autograft bone for mandibular
bone reconstruction.104
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Bone morphogenetic proteins
Furthermore, in total, 15 scientific papers15,18,29,31,32,97–
99,101–103,105,106,109,110 reporting on recombinant human bone
morphogenetic protein-2 (rhBMP-2) as well as five publica-
tions16,17,19,30,33 presenting data on recombinant human bone
morphogenetic protein-7 (rhBMP-7) were eventually in-
cluded in the current systematic approach. Thereby, the brief
summarized studies of Kontaxis et al.,16 Abu-Serriah et al.,19
Boyne,29,101 Busuttil Naudi et al.,30 and Toriumi et al.97 may
give a good general impression of the effectiveness of rhBMPs
regarding the quantity as well as quality of induced bone for
the reconstruction of continuity mandibular defects (Details
can be found in Addendum No. 2 in Supplementary Data).
In summary, rhBMP-2 and rhBMP-7 were studied in
combination with collagen/collagen composite scaf-
folds,15–19,29,32,33,99,101,108,110 poly-D,L-lactide coglycolic
acid based carriers.31,98,102,103 b-TCP30, as well as coralline
hydroxyapatite109 and allogenic bone matrix.97 Regarding
the primary outcome variable bone bridging15–19,29–33,97–
99,101–103,109,110 as well as the co-outcome variables bone
ingrowths17–19,29,30,32,33,97–99,109 and biomechanical test-
ing,16,19,30,33,97 rhBMP-2 and rhBMP-7 demonstrated in
preclinical animal studies their potential as an alternative
to autograft bone for mandibular bone reconstruction in
continuity defects. However, the published results were
not uniform. It should be mentioned that in different re-
ports, rhBMP-2 or rhBMP-7 combined with demineralized
freeze-dried bone allograft,109 polyglycolic co-lactic
acid,102 and a bovine collagen type I carrier wrapped into a
sterno-occipitalis muscle flap17 were not associated with
predictable defect bridging.
In line with these results are the reported effects of rhBMP-
215,31,32,98,99,103,110 and rhBMP-733 for mandibular bone re-
generation in continuity defects. On the other hand, it should
be mentioned that rhBMP-2, in the reports of Zhou et al.109
and Seto et al.,102 as well as rhBMP-7, in the paper of Ayoub
et al.,17 have not always been associated with bony union.
Likewise, in the paper of Ayoub et al.,17 rhBMP-7 was not in
all animals associated with complete bone regeneration.
Human case report
In addition to animal experiments, bone tissue engineering
for reconstruction of mandibular continuity defects has been
investigated in humans. Similar to preclinical models,
FIG. 1. Selection process.
150 CHANCHAREONSOOK ET AL.
considerable interest for therapeutic use has been focused on
the application of autogenous osteogenic tissues or bone
morphogenetic proteins, both of which are combined with a
range of different carrier biomaterials. In total, 11 scientific
papers111–121 reporting on 10 different investigation entities
were finally included in the current systematic review.
Autogenous osteogenic tissues and bone
morphogenetic proteins (Details can be found
in Addendum No. 3 in Supplementary Data)
In summary, transplantation of tissue-engineered autoge-
nous osteogenic tissues without additional application of
Table 1. Excluded Articles: Reporting on Noncontinuity Defects
No Year Authors Journal
1. 1998 Schliephake et al.36 J Oral Maxillofac Surg 56, 616, 1998.
2. 2002 Fisher et al.37 Engineering in Medicine and Biology, 2002. 24th Annual Conference and
the Annual Fall Meeting of the Biomedical Engineering Society EMBS/BMES
Conference, 2002. Proceedings of the Second Joint 2002 Oct 1, pp. 827–828.
3. 2002 Chu et al.38 Biomaterials 23, 1283, 2002.
4. 2003 Gro¨ger et al.39 Scand J Plast Reconstr Surg Hand Surg 37, 129, 2003.
5. 2003 Nakahara et al.40 Tissue Eng 9, 153, 2003.
6. 2004 Abukawa et al.41 J Oral Maxillofac Surg 62, 601, 2004.
7. 2004 Yamada et al.42 Cell Transplant 13, 343, 2004.
8. 2004 Yamada et al.43 Clin Oral Implants Res 15, 589, 2004.
9. 2005 Ito et al.44 J Biomed Mater Res Part A 73, 63, 2005.
10. 2005 Li et al.45 Aust N Z J Surg 75, 1017, 2005.
11. 2005 Marei et al.46 Tissue Eng 11, 751, 2005.
12. 2005 Meyer et al.47 Int J Oral Maxillofac Implants 20, 882, 2005.
13. 2005 Ren et al.48 J Biomed Mater Res Part A 74, 562, 2005.
14. 2006 Ito et al.49 Clin Oral Implants Res 17, 579, 2006.
15. 2007 Mylonas et al.50 J Prosthodont 16, 421, 2007.
16. 2007 Ren et al.51 J Biomater Sci Polym Ed 18, 505, 2007.
17. 2007 Rai et al.52 J Oral Maxillofac Surg 65, 2195, 2007.
18. 2007 Wang et al.53 Biomaterials 28, 3338, 2007.
19. 2007 Zhang et al.54 Biomaterials 28, 4635, 2007
20. 2008 Kuznetsov et al.55 Biomaterials 29, 4211,2008
21. 2008 Tang et al.56 Cell Biol Int 32, 1150, 2008.
22. 2008 Wang et al.57 J Clin Rehab Tissue Eng Res 12, 9762,2008.
23. 2009 Abukawa et al.58 J Oral Maxillofac Surg 67, 335, 2009.
24. 2009 Appleford et al.59 J Biomed Mater Res Part A 89, 1019, 2009.
25. 2009 d’Aquino et al.60 Eur Cells Mater 18, 75, 2009.
26. 2009 Guo et al.61 Acta Biomater 5, 268, 2009.
27. 2009 Jiang et al.62 Biomaterials 30, 4522, 2009.
28. 2009 Schliephake et al.63 Int J Oral Maxillofac Surg 38, 166, 2009.
29. 2009 Schuckert et al.64 Tissue Eng Part A 15, 493, 2009.
30. 2009 Shi et al.65 J Biomater Appl 23, 331, 2009.
31. 2009 Wang et al.66 Biomaterials 30, 2489, 2009.
32. 2009 Yao et al.67 J Biomed Mater Res Part B Appl Biomater 91, 805, 2009.
33. 2009 Yoshimi et al.68 J Craniofac Surg 20, 1523, 2009.
34. 2009 Zhang et al.69 Biomed Mater 4, 045007, 2009.
35. 2009 Zhang et al.70 J Controlled Release 136, 172, 2009.
36. 2009 Zhao et al.71 Bone 45, 517, 2009.
37. 2009 Zheng et al.72 J Dent Res 88, 249, 2009.
38. 2010 Gallego et al.73 Tissue Eng Part A 16, 1179, 2010.
39. 2010 Huang et al.74 J Biomed Mater Res Part A 95, 993, 2010.
40. 2010 Li et al.75 J Biomed Mater Res Part A 95, 973, 2010.
41. 2010 Parrilla et al.76 Arch Otolaryngol Head Neck Surg 137, 463, 2011.
42. 2010 Ribeiro et al.77 J Clin Periodontol 37, 1128, 2010.
43. 2010 Zhao et al.78 Oral Diseases 16, 46, 2010.
44. 2011 Dormer et al.79 J Oral Maxillofac Surg 69, e50, 2011.
45. 2011 Kohgo et al.80 Int J Periodontics Restorative Dent 31, e9, 2011.
46. 2011 Ito et al.81 Int J Oral Maxillofac Implants 26, 947, 2011.
47. 2011 Parrilla et al.82 Head Neck 32, 310, 2010.
48. 2011 Yamada et al.83 Cell Transplant 20, 1003, 2011.
49. 2011 Zhu et al.84 Osteoarthritis Cartilage 19, 743, 2011.
50. 2012 Yeo et al.85 Clin Oral Implants Res 23, 1322, 2012.
51. 2012 Vahabi et al.86 Chang Gung Med J 35, 28, 2012.
52. 2012 Zhou et al.87 Mater Sci Eng C 32, 994, 2012.
53. 2012 Zou et al.88 PLoS One 7, e32355, 2012.
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osteoinductive BMPs119 or in combination with rhBMP-
2115,117,120 as well as rhBMP-7110,111 was associated with re-
stored mandibular continuity in five cases, but in one case,117
no bony union was observed. Furthermore, in 16 patients in
some reports,115,118,121 osteoinductive rhBMP-2 loaded onto
different biomaterials without concomitant transplantation
of autogenous osteogenic tissue was followed by restored
mandibular continuity. Again, this did not occur in one
subject.117 Moreover, in 10 patients rhBMP-7,116 in one pa-
tient native human BMPs111 and in two patients xenogeneic
BMPs112 without concurrent transplantation of autogenous
osteogenic tissue were associated with reconstructed man-
dibular continuity. However, this was not observed in four
subjects treated with xenogeneic BMPs.112
Discussion
Currently, bone tissue engineering can be considered a
highly promising approach and as an alternative bone
source. Well-performed in vitro and in vivo experiments are
essential to determine the suitability of the chosen concept
and to understand the risks before proceeding into the clin-
ical trial.122,123 In vitro studies require a desired monitored
environment that mimics the dynamics of the in vivo condi-
tion by a controlled homogeneity of nutrients media (also in
terms of pH/osmolarity), additional osteogenic stimuli(s),
and providing a physical stimulation as relevant key com-
ponents for bone construction.124 However, the in vitro con-
dition is unable to provide physiological function and is
never exactly the same condition as the in vivo one.124 The
results from in vitro studies do not give direct information or
can be difficult to infer from the in vivo situation,125 but are
rather considered baseline properties.126 For this reason, the
use of animal models is often an essential step in the testing
of tissue engineering before clinical use.
The aims of the present report were to review systemati-
cally preclinical in vivo as well as clinical literature regarding
bone tissue engineering for mandibular continuity defects
and to analyze the effectiveness of this approach for the
treatment of mandibular continuity defects.
In total, 29 publications reporting on animal experiments
and 11 papers presenting human cases could be included in
the present systematic review. The evaluated articles of the
first part of the current review report on tissue-engineered
reconstructions of segmental mandibular body, angle, or
condyle defects in different animal species. Thus, autogenous
bone precursor cells or autogenous osteogenic tissues were
primarily combined with calcium phosphate ceramic scaf-
folds. Regarding bone bridging, bone ingrowth, as well as
biomechanical testing, these tissue-engineered approaches
demonstrated a certain potential as an alternative to auto-
graft bone for mandibular bone reconstruction in continuity
defects. In principle, these results were not unexpected and
were in line with the literature for bone tissue engineering in
general. It is well known that BMSCs are capable of self-
renewal and differentiation into various osteogenic lineage
cells.127 Furthermore, their osteogenic potential has been
demonstrated both in vitro and in vivo. Consequently, BMSCs
became a major seed cell source for bone tissue engineering.
Moreover, many previous studies have succeeded in re-
pairing bone defects by using BMSCs in animal models as
well as in humans.24,127–129
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Besides, due to their compositional similarities to bone
mineral, their excellent biocompatibility, osteoconductivity,
as well as drug delivery potential, calcium phosphates, es-
pecially tricalcium phosphate and hydroxyapatite, are the
most widely used bone substitutes in bone tissue engineer-
ing.127 Moreover, BMSCs seeded onto calcium phosphate
scaffolds induced ectopic bone formation in a mice model.129
However, the currently presented favorable data for bone
tissue-engineered constructs as compared with scaffolds
alone have to be interpreted with caution. In principle,
sample size and thereby statistical power of the reviewed
preclinical in vivo experiments tended to be low. For exam-
ple, the compared 12 weeks of bone bridging and bone in-
growths106 originate from only two animals/segmental
defects without statistical analysis. Another example is the 3
months data.25 Their statistically significant better biome-
chanical results ( p< 0.05) for tissue-engineered bone as
compared with the scaffold alone originate from not more
than three animals/segmental defects. Thus, with an as-
sumed a-error of 0.05, post hoc analysis for, for example,
compression strength reveals a statistical power as low as
0.385. Furthermore, next to autogenous bone precursor cells
or autogenous osteogenic tissues, bone morphogenetic pro-
teins (i.e.: rhBMP-2 and rhBMP-7) were studied. Pre-
dominantly, rhBMP-2 and rhBMP-7 were combined with
collagen/collagen composite scaffolds. However, a few pa-
pers examined combinations with poly-D,L-lactide cogly-
colic acid as well as calcium phosphate carriers. Regarding
bone bridging, bone ingrowth, as well as biomechanical
testing, these tissue-engineered approaches displayed some
potential as an alternative to autograft bone for mandibular
bone reconstruction in continuity defects. However, the
published results were not uniform. For example, rhBMP-2
or rhBMP-7 combined with a bovine collagen type I carri-
er,17 polyglycolic co-lactic acid102 as well as demineralized
freeze-dried bone allograft109 were not associated with
predictable defect bridging. Overall, the published out-
comes for bone morphogenetic proteins were not surprising
and were in line with the reports for bone tissue engineer-
ing in general. The osteoinductive potential of BMP-2
and BMP-7130 as well as the general importance of carrier
selection in conjunction with growth factor applica-
tion15,115,131–133 are well known. In addition, for these re-
viewed preclinical in vivo experiments, sample size and
thereby transferability tended to be low. For instance, the 3
months bone bridging data and the found wide range of
mechanical properties of Abu-Serriah et al.19 were obtained
from not more than six animals/segmental defects. Another
good example is the publication of Boyne.29 Their 5 months
of bone bridging and bone histology data originate from
only three animals/segmental defects. Unfortunately, a
meta-analytical approach to increase the power of statistical
analysis by pooling the results of all retrieved available
trials was not feasible. Research of results that are combined
in a meta-analysis should preferably be done in a similar
manner. As shown in Table 3, this is clearly not the case for
the presently included papers. The publications, which
were eligible for inclusion in the present study, display
experimental variability for the utilized animal model, the
anatomical site of reconstruction, the used bone tissue
engineering approach, the number of enrolled animals/
defects, and the healing time after reconstruction.
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Apart from BMPs, alternative growth factors may serve as
potential therapeutic agents to enhance bone and cartilage
formation; for example, recombinant human platelet-derived
growth factor (rhPDGF), transforming growth factor-beta
(TGF-b), fibroblast growth factor, recombinant human
growth/differentiation factor-5 (rhGDF-5), and insulin-like
growth factor.134 PDGF is known to simulate angiogenesis
through activation of the macrophages,134 which secrete
factors cells to form new capillary sprouts. TGF-b1 has been
proved to promote cartilage regeneration.79 rhGDF-5 has the
potential to grow the same type of tissues as where it is
naturally present. Its possibility of being used in a tissue
engineering approach has been reported for the regeneration
of dento-alveolar tissues.135,136
However, a single dose of an exogenous protein will not
adequately induce a biologic response in compromised
tissue conditions. Gene therapy is another concept in which
genetic information is transferred into target cells. Subse-
quently, the cells synthesize the endogenous protein en-
coded by the gene.137 The process that involves the transfer
of functional genetic information into the target cell is
known as transduction. This is accomplished when the re-
combinant vector (virus) which contains the therapeutic
DNA binds to the cell, usually via a receptor-mediated
process, and then enters that cell. The DNA passes into the
nucleus of the cell, where it may become integrated into the
host genome or may remain extrachromosomal. The trans-
duced cells can then produce and secrete the growth factor
encoded by the DNA98-100.56,70 In this review, it was found
that the use of gene therapy was being applied in the re-
construction of mandibular continuity defects in animals
and humans. On the other hand, gene therapy has been
reported for the repair of the mandibular condyle and
temporomandibular joints and was found to support min-
eralized tissue formation.138–140
In the second part of the review, 11 papers, presenting
human cases regarding tissue engineered reconstruction of
mandibular continuity defects, were eventually included.
The review included the reports on microvascular tissue
transfer of prefabricated bones in the study. Although, these
techniques belong to tissue regeneration, they are important
for the reconstructive surgeon. Therefore, transplantation of
tissue-engineered autogenous osteogenic tissues without
additional application of osteoinductive BMPs or in combi-
nation with rhBMP-2/rhBMP-7 produced restored mandib-
ular continuity in five out of six cases. Furthermore, in 29 out
of 34 patients, the application of native human BMPs, xe-
nogeneic BMPs, rhBMP-2, or rhBMP-7 without concomitant
transplantation of autogenous osteogenic tissue was associ-
ated with complete bony defect bridging. Unfortunately, no
direct comparison of the results with autogenous bone
transplantation can be done due to lack of direct control.
However, Herford and Cicciu`120 stated that bone growth
cytokines can be considered a predictable alternative to tra-
ditional grafting techniques. In general, these results were
not astonishing and in line with the literature.15,115,141–144
Thus, it might be assumed that these tissue-engineered ap-
proaches may have, in certain selected patients, some po-
tential as an alternative to autograft bone for mandibular
bone reconstruction in continuity defects. However, it should
be underlined that until now only a few successfully treated
cases have been published. Furthermore, to date, the clinical
predictability has to be questioned. An additional issue is the
limited license of the use of rhBMP-2 in oral and maxillofa-
cial surgery. According to the Center for Devices and Radi-
ological Health (CDRH) of the U.S. Food and Drug
Administration (FDA), rhBMP-2 is not licensed for use in
surgery of mandibular continuity defects and may only be
applied for sinus augmentation and localized alveolar ridge
augmentation.
Conclusions
The reviews showed a various study methodology, review
period, and different control groups. Not all studies com-
pared the finding with a reconstruction with autologous
bone substitute. None of the human studies were performed
as a randomized control trial study. Within the limits of
this systematic approach to the literature regarding tissue-
engineered bone reconstruction in continuity defects of the
mandible, we conclude that (1) published preclinical in vivo
as well as clinical data are limited, and (2) tissue-engineered
approaches demonstrate some clinical potential as an alter-
native to autograft bone. The future research in this area
needs to include process evaluation research in order to de-
fine the characteristics contributing to the success and failure
of any intervention.
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